港股创新药50ETF（513780）盘中价格创历史新高，年内涨超45%！多家创新药企官宣BD交易订单

Group 1: Market Performance - The Hang Seng Index rose by 0.72% and the Hang Seng Tech Index increased by 1.01% on June 4 [1] - The CSI Hong Kong Stock Connect Innovative Drug Index surged by 3.79%, with notable gains from companies like Innovent Biologics (up 15.07%) and Zai Lab (up 10.97%) [1] - The Hong Kong Innovative Drug 50 ETF (513780) saw a 4% increase in early trading, reaching a historical high of 1.391 yuan, with a trading volume of 299 million yuan [1] Group 2: Fund Flows and ETF Performance - The Hong Kong Innovative Drug 50 ETF has experienced a net inflow of 63.34 million yuan over the past three trading days, with a total circulation of 419 million shares and a market size of 553 million yuan [1] - The ETF has gained over 45% year-to-date [1] Group 3: Business Development Transactions - In May, at least six domestic innovative drug companies announced business development (BD) transactions, primarily involving cross-border collaborations with foreign pharmaceutical companies [2] - The total value of BD transactions in the innovative drug sector is projected to increase from 9.2 billion USD in 2020 to 52.3 billion USD by 2024, with upfront payments rising from 600 million USD to 4.1 billion USD [2] Group 4: Industry Outlook - CITIC Securities predicts a structural turning point for the pharmaceutical industry by 2025, driven by continuous policy optimization and the growth of innovative and biological drugs [3] - The pharmaceutical market is expected to exceed 8 trillion yuan, supported by an aging population and upgraded health consumption [3] - The internationalization of Chinese pharmaceutical companies is accelerating, with innovative drug exports becoming a significant growth driver [3]